Adalimumab ameliorates memory impairments and neuroinflammation in chronic cerebral hypoperfusion rats

Vascular dementia (VaD) is the second most common type of dementia worldwide. Although there are five FDA-approved drugs for the treatment of Alzheimer’s disease (AD), none of them have been applied to treat VaD. Adalimumab is a TNF-α inhibitor that is used for the treatment of autoimmune diseases s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Aging (Albany NY)
Hlavní autoři: Xu, Jing-Jing, Guo, Si, Xue, Rui, Xiao, Lin, Kou, Jun-Na, Liu, Yu-Qiong, Han, Jun-Ya, Fu, Jing-Jie, Wei, Na
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals 2021
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202885/
https://ncbi.nlm.nih.gov/pubmed/34030135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.203009
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky